Related Experiment Videos

Improved diagnostic capability, rather than biologics, reduces surgical rates in Chinese Crohn's disease patients: A

Jian Wan¹, Zhuo Wang², Jun Shen³

¹State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.

Chinese Medical Journal

|September 17, 2026

Abstract

Background:

Surgical rates for Crohn's disease (CD) are declining globally. However, the driving factors remain unclear, particularly in newly industrialized countries. We aimed to evaluate the impact of diagnostic capacity and treatment with biologics on surgical rates among Chinese CD patients.

Methods:

Data of CD patients from January 2000 to January 2024 were extracted from 8 sites of the Chinese database for inflammatory bowel disease. Trends in cross-sectional imaging use, surgically diagnosed proportion, medical treatment, and surgery for CD were described. Cumulative surgical rates were compared using Kaplan-Meier method with log-rank test. Time-dependent Cox models were used to identify factors associated with surgery risk, and propensity score matching (PSM) was applied to validate the findings.

Results:

In total, 1354 patients were included, with a median follow-up of 5.99 years. The cumulative 5-year surgical rate decreased from 30.96% in 2000-2012 to 21.57% in 2013-2024 (log-rank P <0.001). The use of cross-sectional imaging increased from 2.00% in 2000-2004 to 82.81% in 2020-2024. The proportion of surgically diagnosed patients declined from 13.68% in 2000-2012 to 6.21% in 2013-2024. Multivariate Cox analysis showed that diagnosis in 2013-2024 (hazard ratio [HR] 0.74, 95% confidence interval [CI]: 0.59-0.91, P = 0.006) was independently associated with a lower risk of surgery, whereas biologic use (HR 0.93, 95% CI: 0.71-1.22, P = 0.604) was not. Sensitivity analyses excluding surgically diagnosed patients demonstrated similar surgical rates between the two cohorts. PSM and subgroup analyses confirmed these trends.

Conclusions:

Surgical rates among Chinese CD patients have significantly decreased over the past two decades, in parallel with improvements in diagnosis. Enhancements in diagnostic pathways within broader systemic healthcare upgrades are strongly associated with reduced surgical risk, whereas increased use of biologics is not.

Keywords:

Biologics China Crohn’s disease Diagnosis Registry data Surgery Trends

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Inflammatory Bowel Disease V: Surgical Management

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:

Articles linked to this work by shared authors, journal, and citation graph.

PHPT1/Ocnus negatively regulates the JAK/STAT pathway to control cell survival.

iScience·2026

VGLL4 enhances PDK4 transcription and promotes metabolic dysfunction-associated fatty liver disease.

EMBO reports·2026

Madecassic acid attenuates sepsis-associated acute lung injury by regulating the PI3K/AKT/mTOR pathway to mediate anti-inflammatory, antioxidant and anti-apoptotic effects.

Pakistan journal of pharmaceutical sciences·2026

miR-7641: A Novel Diagnostic Biomarker for Rheumatoid Arthritis That Exerts Protective Effects by Targeting TNFSF10.

International journal of immunogenetics·2026

Impact of SA-related visual characteristics on driver takeover reaction time in L3 automated vehicles: an eye-movement-based evaluation method.

Frontiers in psychology·2026

Optimal Transport-Based Heterogeneous Federated Learning for Chest X-Rays.

Sensors (Basel, Switzerland)·2026

See all related articles